HK inno.N licenses in mAbxience's denosumab biosimilar
mAbxience II Biosimilar Forum
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
